Equities Analysts Issue Forecasts for AC Immune Q2 Earnings

AC Immune SA (NASDAQ:ACIU) – HC Wainwright boosted their Q2 2025 earnings estimates for shares of AC Immune in a research report issued to clients and investors on Thursday, May 1st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.21) for the quarter, up from their previous forecast of ($0.22). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for AC Immune’s current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for AC Immune’s Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.85) EPS and FY2026 earnings at ($0.78) EPS.

AC Immune Trading Up 3.0 %

AC Immune stock opened at $1.72 on Monday. AC Immune has a 12-month low of $1.43 and a 12-month high of $4.98. The firm has a market capitalization of $172.71 million, a price-to-earnings ratio of -3.74 and a beta of 1.62. The firm has a 50 day moving average of $1.92 and a 200 day moving average of $2.56.

AC Immune (NASDAQ:ACIU) last released its earnings results on Wednesday, April 30th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01. The company had revenue of $1.12 million for the quarter, compared to analysts’ expectations of $1.99 million.

Institutional Trading of AC Immune

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC boosted its holdings in AC Immune by 14.6% in the 4th quarter. Renaissance Technologies LLC now owns 740,198 shares of the company’s stock worth $1,999,000 after buying an additional 94,191 shares during the period. Northern Trust Corp bought a new position in shares of AC Immune in the fourth quarter worth about $1,088,000. Dimensional Fund Advisors LP grew its position in shares of AC Immune by 130.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company’s stock worth $355,000 after purchasing an additional 74,358 shares in the last quarter. Geode Capital Management LLC lifted its holdings in AC Immune by 9.9% in the 4th quarter. Geode Capital Management LLC now owns 64,090 shares of the company’s stock worth $173,000 after purchasing an additional 5,794 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in AC Immune in the 4th quarter worth approximately $118,000. 51.36% of the stock is owned by hedge funds and other institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.